|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy显示文摘Hepatitis due to hepatitis B virus(HBV) reactivation can be severe and potentially fatal, but is preventable. HBV reactivation is most commonly reported in patients receiving cancer chemotherapy, especially rituximabcontaining therapy for hematological malignancies and those receiving stem cell transplantation. All patients with hematological malignancies receiving anticancer therapy should be screened for active or resolved HBV infection by blood tests for hepatitis B surface antigen(HBs Ag) and antibody to hepatitis B core antigen(antiHBc). Patients found to be positive for HBs Ag should be given prophylactic antiviral therapy to prevent HBV reactivation. For patients with resolved HBV infection, no standard strategy has yet been established to prevent HBV reactivation. There are usually two options. One is pre-emptive therapy guided by serial HBV DNA monitoring, whereby antiviral therapy is given as soon as HBV DNA becomes detectable. However, there is little evidence regarding the optimal interval and period of monitoring. An alternative approach is prophylactic antiviral therapy, especially for patients receiving highrisk therapy such as rituximab, newer generation of anti-CD20 monoclonal antibody, obinutuzumab or hematopoietic stem cell transplantation. This strategy may effectively prevent HBV reactivation and avoid the inconvenience of repeated HBV DNA monitoring. Entecavir or tenofovir are preferred over lamivudine as prophylactic therapy. Although there is no well-defined guideline on the optimal duration of prophylactic therapy, there is growing evidence to recommend continuing prophylactic antiviral therapy for at least 12 mo after cessation of chemotherapy, and even longer for those who receive rituximab or who had high serum HBV DNA levels before the start of immunosuppressive therapy. Many novel agents have recently become available for the treatment of hematological malignancies, and these agents may be associated with HBV reactivation. Although there is currently limited evidence to guide the optimal preventive measures, we recommend antiviral prophylaxis in HBs Ag-positive patients receiving novel treatments, especially the Bruton tyrosine kinase inhibitors and the phosphatidylinositol 3-kinase inhibitors, which are B-cell receptor signaling modulators and reduce proliferation of malignant B-cells. Further studies are needed to clarify the risk of HBV reactivation with these agents and the best prophylactic strategy in the era of targeted therapy for hematological malignancies. | Man Fai Law Rita Ho Carmen KM Cheung Lydia HP Tam Karen Ma Kent CY So Bonaventure Ip Jacqueline So Jennifer Lai Joyce Ng Tommy HC Tam | 2016 | World Journal of Gastroenterology2016，22，28： | 10 |
| 2 | High-performance oxygen reduction and evolution carbon catalysis: From mechanistic studies to device integration显示文摘能容易集成于存在的高效、便宜的氧减小和进化催化剂的发展设备为利用 O 2-H2 O 化学,例如再生燃料房间和金属空气电池。此处,我们报导 NH 3-activated 做 N 的层次碳(NHC ) 催化剂经由一条可伸缩的线路综合了,并且表明它的设备集成。NHC 催化剂为氧减小反应(ORR ) 和氧进化反应(OER ) 展出了好性能,当综合时,借助于电气化学的研究和评估示威了进一个再生燃料房间的氧电极。为 ORR 和 OER 观察的活动比得上最先进的磅和红外催化剂在碱的环境完成的那些。我们进一步通过密度为电气化学的活动作为活跃地点识别了碳缺点的关键角色功能的理论计算和高分辨率的 TEM 可视化。这个工作加亮 NHC 的潜力在再生燃料房间并且可能代替商业宝贵金属为断断续续的可更新的精力的划算的存储的金属空气电池。 | John W. F. To Jia Wei Desmond Ng Samira Siahrostami Ai Leen Koh Yangjin Lee Zhihua Chen Kara D. Fong Shucheng Chen Jiajun He Won-Gyu Bae Jennifer Wilcox Hu Young Jeong Kwanpyo Kim Felix Studt Jens K. Nфrskov Thomas F. Jaramillo Zhenan Bao | 2017 | Nano Research2017，10，4： | 4 |
| 3 | 克隆测序确认HLA新等位基因B~*3712^(★○)显示文摘目的:由于技术原理的限制,目前尚不能对所有的HLA等位基因进行严格的区分,特别是以往没有发现的新基因序列只能通过测序的方法解决,然而,当遇到等位基因杂合时,测序给出的结果仍然无法确认新的序列改变发生在等位基因的哪一侧,这时需要用分子生物学方法分离杂合子然后进行测序才能确定新的基因序列。采用基因克隆方法确认HLA新等位基因。方法:实验于2006-01/05在河南省红十字血液中心HLA实验室,美国海军骨髓库HLA实验室完。成造血干细胞血样由中华骨髓库提供。采用荧光微珠HLA分型方法对中华骨髓库捐献者血样进行HLA分型检测,无法给出确切结果的摸棱两可结果标本用基因克隆(TOPO TA Cloning)、DNA测序的方法确认新的HLA基因序列。结果:通过克隆分离杂台等位基因,再进行测序确认发现新的序列与B~*3709相比,出现4个核苷酸改变:1.355nt C>A,2.363nt C>G,3.412ntG>A,4 477nt C>G,而且均发生在HLA-B基因外显子3(exon 3)。4处改变引起氨基酸编码改变:①编码95 CTC>ATC,氨基酸改变L>I(亮氨酸>异亮氨酸)。②97 AGC>AGG,S>R(丝氨酸>精氨酸)。③114 GAC>AAC D>N(天门冬氨酸>天冬酰胺)。④135 GCC>GCG A=A无氨基酸改变。结论:①新的基因序列已经在GenBnak注册,被WHO的HLA因子命名委员会得到正式命名为HLA-B~*3712基因。②基因克隆是确认HLA新基因的根本方法。 | 张伯伟 邢培清 赵磊 Ana Lazaro Jennifer Ng | 2007 | 中国组织工程研究与临床康复2007，11，50： | 3 |
| 4 | Googling for a diagnosis-use of Google as a diagnostic aid:internet based study显示文摘 | Hangwi Tang Jennifer Hwee Kwoon Ng | 2006 | BMJ2006，333，： | 1 |
| 5 | HLA antigen sharing be-tween mother and fetus as a risk factor for eclampsia and pre-eclampsia显示文摘 | Robert JB Gry P Jennifer Ng | 2010 | Hum Immunol2010，71，： | 1 |
| 6 | Validation of a Static Franz Diffusion Cell System for In Vitro Permeation Studies显示文摘 | Shiow-Fern Ng Jennifer J. Rouse Francis D. Sanderson Victor Meidan Gillian M. Eccleston | 2010 | AAPS PharmSciTech2010，，3： | 1 |
| 7 | MicroRNA-143 is downregulated in breast cancer and regulates DNA methyltransferases 3A in breast cancer cells显示文摘 | Enders K. O. Ng Rufina Li Vivian Y. Shin Jennifer M. Siu Edmond S. K. Ma Ava Kwong | 2014 | Tumor Biology2014，，3： | 1 |
| 8 | MicroRNA-150: A Novel Marker of Left Ventricular Remodeling After Acute Myocardial Infarction显示文摘 | Yvan Devaux Melanie Vausort Gerry P. McCann Jennifer Zangrando Dominic Kelly Naveed Razvi Lu Zhang Leong L. Ng Daniel R. Wagner Iain B. Squire | 2013 | Circulation: Cardiovascular Genetics2013，，： | 1 |
| 9 | Contemporary trends in necrotizing soft-tissue infections in the United States显示文摘 | Charles M. Psoinos Julie M. Flahive Joshua J. Shaw YouFu Li Sing Chau Ng Jennifer F. Tseng Heena P. Santry | 2013 | Surgery2013，，6： | 1 |
| 10 | Weather changes and pain rheumatology patients 显示文摘 | Jennifer NG David Scott Ashish Taneja | 2004 | APLAR Journal Rheumatology2004，，7： | 1 |
| 11 | Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus显示文摘AIM: To determine the safety profile of new hepatitis C virus(HCV) treatments in liver transplant(LT) recipients with recurrent HCV infection.METHODS: Forty-two patients were identified with recurrent HCV infection that underwent LT at least 12 mo prior to initiating treatment with a Sofosbuvir-based regimen during December 2013-June 2014. Cases were patients who experienced hepatic decompensation and/or serious adverse events(SAE) during or within one month of completing treatment. Controls had no evidence of hepatic decompensation and/or SAE. HIVinfected patients were excluded. Cumulative incidence of decompensation/SAE was calculated using the Kaplan Meier method. Exact logistic regression analysis was used to identify factors associated with the composite outcome. RESULTS: Median age of the 42 patients was 60 years [Interquartile Range(IQR): 56-65 years], 33%(14/42) were female, 21%(9/42) were Hispanic, and 9%(4/42) were Black. The median time from transplant to treatment initiation was 5.4 years(IQR: 2.1-8.8 years). Thirteen patients experienced one or more episodes of hepatic decompensation and/or SAE. Anemia requiring transfusion, the most common event, occurred in 62%(8/13) patients, while 54%(7/13) decompensated. The cumulative incidence of hepatic decompensation/SAE was 31%(95%CI: 16%-41%). Risk factors for decompensation/SAE included lower pre-treatment hemoglobin(OR = 0.61 per g/d L, 95%CI: 0.40-0.88, P < 0.01), estimated glomerular filtration rate(OR = 0.95 per m L/min per 1.73 m^2, 95%CI: 0.90-0.99, P = 0.01), and higher baseline serum total bilirubin(OR = 2.43 per mg/d L, 95%CI: 1.17-8.65, P < 0.01). The sustained virological response rate for the cohort of 42 patients was 45%, while it was 31% for cases.CONCLUSION: Sofosbuvir/ribavirin will continue to be used in the post-transplant population, including those with HCV genotypes 2 and 3. Management of anemia remains an important clinical challenge. | Neal Patel Kian Bichoupan Lawrence Ku Rachana Yalamanchili Alyson Harty Donald Gardenier Michel Ng David Motamed Viktoriya Khaitova Nancy Bach Charissa Chang Priya Grewal Meena Bansal Ritu Agarwal Lawrence Liu Gene Im Jennifer Leong Leona Kim-Schluger Joseph Odin Jawad Ahmad Scott Friedman Douglas Dieterich Thomas Schiano Ponni Perumalswami Andrea Branch | 2016 | World Journal of Gastroenterology2016，22，9： | 1 |
| 12 | Predictive Value of the Index of Microcirculatory Resistance in Patients With ST-Segment Elevation Myocardial Infarction显示文摘 | William F. Fearon Maulik Shah Martin Ng Todd Brinton Andrew Wilson Jennifer A. Tremmel Ingela Schnittger David P. Lee Randall H. Vagelos Peter J. Fitzgerald Paul G. Yock Alan C. Yeung | 2008 | Journal of the American College of Cardiology2008，，5： | 1 |
| 13 | Systematic Review of Early Surgery for Chronic Pancreatitis: Impact on Pain, Pancreatic Function, and Re-intervention显示文摘 | Catherine J. Yang Lindsay A. Bliss Emily F. Schapira Steven D. Freedman Sing Chau Ng John A. Windsor Jennifer F. Tseng | 2014 | Journal of Gastrointestinal Surgery2014，，： | 1 |
| 14 | Hepatitis B virus–DNA level and basal core promoter A1762T/G1764A mutation in liver tissue independently predict postoperative survival in hepatocellular carcinoma显示文摘 | Chau‐Ting Yeh Mary So Jennifer Ng Han‐Wen Yang Ming‐Ling Chang Ming‐Wei Lai Tse‐Ching Chen Chun‐Yen Lin Ta‐Sen Yeh Wei‐Chen Lee | 2010 | Hepatology2010，，6： | 1 |
| 15 | Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results显示文摘AIM To assess the real-world effectiveness and cost of simeprevir(SMV), and/or sofosbuvir(SOF)-based therapy for chronic hepatitis C virus(HCV) infection.METHODS The real-world performance of patients treated with SMV/SOF ± ribavirin(RBV), SOF/RBV, and SOF/RBV with pegylated-interferon(PEG) were analyzed in a consecutive series of 508 patients with chronic HCV infection treated at a single academic medical center. Patients with genotypes 1 through 4 were included. Rates of sustained virological response-the absence of a detectable serum HCV RNA 12 wk after the end of treatment [sustained virological response(SVR) 12]-were calculated on an intention-to-treat basis. Costs were calculated from the payer's perspective using Medicare/Medicaid fees and Redbook Wholesale Acquisition Costs. Patient-related factors associated with SVR12 were identified using multivariable logistic regression.RESULTS SVR 12 rates were as follows: 86%(95%CI: 80%-91%)among 178 patients on SMV/SOF ± RBV; 62%(95%CI: 55%-68%) among 234 patients on SOF/RBV; and 78%(95%CI: 68%-86%) among 96 patients on SOF/PEG/RBV. Mean costs-per-SVR 12 were $174442(standard deviation: ± $18588) for SMV/SOF ± RBV; $223003(± $77946) for SOF/RBV; and $126496(± $31052) for SOF/PEG/RBV. Among patients on SMV/SOF ± RBV, SVR12 was less likely in patients previously treated with a protease inhibitor [odds ratio(OR): 0.20, 95%CI: 0.06-0.56]. Higher bilirubin(OR: 0.47, 95%CI: 0.30-0.69) reduced the likelihood of SVR12 among patients on SOF/RBV, while FIB-4 score ≥ 3.25 reduced the likelihood of SVR 12(OR: 0.18, 95%CI: 0.05-0.59) among those on SOF/PEG/RBV. CONCLUSION SVR 12 rates for SMV and/or SOF-based regimens in a diverse real-world population are comparable to those in clinical trials. Treatment failure accounts for 27% of costs. | Kian Bichoupan Neeta Tandon James F Crismale Joshua Hartman David Del Bello Neal Patel Sweta Chekuri Alyson Harty Michel Ng Keith M Sigel Meena B Bansal Priya Grewal Charissa Y Chang Jennifer Leong Gene Y Im Lawrence U Liu Joseph A Odin Nancy Bach Scott L Friedman Thomas D Schiano Ponni V Perumalswami Douglas T Dieterich Andrea D Branch | 2017 | World Journal of Virology2017，6，4： | 1 |
| 16 | Redefining Mortality After Pancreatic Cancer Resection显示文摘 | James Edward Carroll Jillian K. Smith Jessica P. Simons Melissa M. Murphy Sing Chau Ng Shimul A. Shah Zheng Zhou Jennifer F. Tseng | 2010 | Journal of Gastrointestinal Surgery2010，，11： | 1 |
| 17 | Perioperative Mortality for Management of Hepatic Neoplasm: A Simple Risk Score显示文摘 | Jessica P. Simons Joshua S. Hill Sing Chau Ng Shimul A. Shah Zheng Zhou Giles F. Whalen Jennifer F. Tseng | 2009 | Annals of Surgery2009，，6： | 1 |
| 18 | Perioperative Mortality for Management of Hepatic Neoplasm: A Simple Risk Score显示文摘 | Jessica P. Simons Joshua S. Hill Sing Chau Ng Shimul A. Shah Zheng Zhou Giles F. Whalen Jennifer F. Tseng | 2009 | Annals of Surgery2009，，6： | 1 |
| 19 | In-Hospital Mortality for Liver Resection for Metastases: A Simple Risk Score显示文摘 | Jessica P. Simons Sing Chau Ng Joshua S. Hill Shimul A. Shah Andreea Bodnari Zheng Zhou Jennifer F. Tseng | 2009 | Journal of Surgical Research2009，，1： | 1 |
| 20 | Impact of diabetes mellitus on survival in South East Asian patients with congestive heart failure due to left ventricular systolic dysfunction显示文摘 | Raymond Lee Siew-Pang Chan Jennifer Wong Diana Lau Kheng-Thye Ho Kenneth Ng | 2008 | International Journal of Cardiology2008，，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员